Pfizer Inc

PFE

Equity

ISIN US7170811035 / Valor 962004

New York Stock Exchange, Inc (2024-11-21)

USD 25.13+0.76%

Pfizer Inc
UMushroom community rating:

5.00 2 votes No rating yet

NegativeNeutralPositive

About company

Pfizer Inc. is a global pharmaceutical corporation that engages in the discovery, development, manufacture, and marketing of a wide range of healthcare products. Its operations span across various segments including innovative health and established health products, focusing on areas such as internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases. Pfizer is known for its commitment to research and development, aiming to address unmet medical needs and improve patient outcomes. The company has made significant strides in the pharmaceutical industry by launching initiatives like an online site for up-to-date information on its U.S. post-marketing commitments, which underscores its dedication to transparency and safety in medicine. Additionally, Pfizer has expanded its reach into animal health through its Agricultural Division, and has ventured into regenerative medicine with the establishment of its Global Regenerative Medicine Unit. The acquisition of Mack Illertissen and the strategic integration of Hospira's portfolio of biosimilars highlight Pfizer's efforts to broaden its product offerings and strengthen its position in the global market. By segmenting its commercial operations into innovative and value business lines, Pfizer aims to cater to both developed and emerging markets, leveraging its scientific expertise and global scale to meet diverse healthcare needs.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the second quarter of 2024, Pfizer Inc. reported revenues of $13.3 billion, marking a 2% increase compared to the same period in 2023. This growth was driven by a 3% operational increase, despite an anticipated decline in COVID-19 related revenues. Excluding contributions from Comirnaty and Paxlovid, Pfizer's revenues grew by 14% operationally.

Adjusted Earnings Per Share

Pfizer Inc. reported an adjusted diluted EPS of $0.60 for the second quarter of 2024. This figure includes a $1.3 billion one-time cost for the company's Manufacturing Optimization Program, which negatively impacted the reported diluted EPS by $0.18. The adjusted EPS reflects the company's strong performance in its non-COVID product portfolio.

Full-Year Guidance

Pfizer Inc. has raised its full-year 2024 revenue guidance to a range of $59.5 to $62.5 billion, up from the previous range of $58.5 to $61.5 billion. Additionally, the company has increased its adjusted diluted EPS guidance to a range of $2.45 to $2.65, reflecting confidence in its business performance and strategic initiatives.

Cost Savings Initiatives

Pfizer Inc. launched a Manufacturing Optimization Program in the second quarter of 2024, which is expected to yield approximately $1.5 billion in cost savings by the end of 2027. This initiative is part of the company's broader strategy to realign its cost base and enhance future margin expansion.

Capital Allocation

During the first six months of 2024, Pfizer Inc. reinvested $5.2 billion into internal research and development projects and approximately $200 million into business development transactions. The company also returned $4.8 billion to shareholders through cash dividends, amounting to $0.84 per share of common stock.

Summarized from source with an LLMView Source

Key figures

-17.1%1Y

-50.5%3Y

-25.2%5Y

Performance

24.3%1Y

26.3%3Y

27.5%5Y

Volatility